Market Overview:
The global hypoglycemic drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetes treatment. The global hypoglycemic drugs market is segmented on the basis of type into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and other types. The insulin segment is expected to dominate the global hypoglycemic drugs market during the forecast period owing to its high usage rates for treating both type 1 and type 2 diabetes mellitus (DM). The DPP-4 inhibitors segment is projected to grow at a higher CAGR than other segments during the forecast period due to their high efficacy in controlling blood sugar levels and low incidence of side effects. On the basis of application,the global hypoglycemic drugs market is divided into type 1 DM and type 2 DM. Type 2 DM accounts for a larger share of this market owingtoits high prevalence worldwide.
Product Definition:
Hypoglycemic drugs are medications used to treat low blood sugar. They work by stimulating the release of insulin from the pancreas or by blocking the absorption of sugar from the intestines. Hypoglycemic drugs are important for treating diabetes and other conditions that can cause low blood sugar.
Insulin:
Insulin is a hormone, which facilitates the entry of glucose into the blood cells. The body's inability to produce an appropriate amount of insulin leads to hypoglycemia or low blood sugar. Insulin is produced by beta cells in the human body and functions by stimulating cell growth and inhibiting certain chemical reactions that lead to cellular damage. In addition, it helps remove toxins from human tissues and organs via K+ (potassium) channels present inside human cells.
DPP-4:
DPP-4 (Dextrose Phosphate Parenteral 4%) is a prescription drug used to treat hypoglycemia in patients with type 1 diabetes and certain other conditions. It is also used as an intravenous infusion therapy for the treatment of hypoglycemia in patients with type 2 diabetes. DPP-4 works by increasing the level of glucose in the blood, which helps to normalize blood sugar levels.
Application Insights:
On the basis of application, the global hypoglycemic drugs market is segmented into type 1 and type 2 diabetes. In 2017, type 1 diabetes dominated the market with a share of over 90%. Increasing incidence rates of this disease coupled with rising awareness levels are expected to drive demand for insulin in the coming years.
Type 2 diabetes is anticipated to be one of fastest growing applications owing to increasing prevalence levels and changing lifestyles. This can be attributed to excessive consumption of calories through food as well as beverages that contain sugar or high fructose corn syrup, lack physical exercise and not maintaining a healthy diet plan along with other causes such as obesity which results in insulin resistance leading to increased requirement for medication among patients suffering from this condition.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of companies, which are engaged in developing and commercializing novel drugs for diabetes management. Moreover, increasing prevalence of obesity and other metabolic disorders is also expected to drive regional growth over the forecast period. Asia Pacific region is anticipated to witness lucrative CAGR during the same period owing to rising healthcare expenditure by governments as well as private organizations, growing awareness about early diagnosis and treatment methods for diabetes, along with high unmet medical needs pertaining to glycemic control in this region. Furthermore Hypo-Allergan PLC; Novo Nordisk A/S; Merck KGaA; Sanofi; Eli Lilly & Co.; Janssen Pharmaceuticals Inc.; Takeda Pharmaceuticals International Ltd.; Pfizer Inc.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for effective and affordable hypoglycemic drugs.
- Technological advancements in drug delivery: Drug delivery technologies are evolving rapidly, providing new opportunities for the development of novel hypoglycemic drugs. This is likely to boost the growth of the hypoglycemic drugs market in coming years.
- Growing awareness about diabetes and its treatment options: There has been a growing awareness about diabetes and its treatment options among people around the world in recent years. This has led to an increase in demand for effective hypoglycemic drugs therapies..
Scope Of The Report
Report Attributes
Report Details
Report Title
Hypoglycemic Drugs Market Research Report
By Type
Insulin, DPP-4, GLP-1, SGLT-2, Other
By Application
Type 1 Diabetes, Type 2 Diabetes
By Companies
Sanofi, Merck & Co., Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Novartis, Johnson & Johnson, AstraZeneca, Takeda, Bayer, Tonghua DongBao, Hua Dong
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Hypoglycemic Drugs Market Report Segments:
The global Hypoglycemic Drugs market is segmented on the basis of:
Types
Insulin, DPP-4, GLP-1, SGLT-2, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 1 Diabetes, Type 2 Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Merck & Co.
- Novo Nordisk
- Eli Lilly
- Boehringer Ingelheim
- Novartis
- Johnson & Johnson
- AstraZeneca
- Takeda
- Bayer
- Tonghua DongBao
- Hua Dong
Highlights of The Hypoglycemic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin
- DPP-4
- GLP-1
- SGLT-2
- Other
- By Application:
- Type 1 Diabetes
- Type 2 Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hypoglycemic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hypoglycemic drugs are medications that help to lower blood sugar levels. They are often used to treat type 2 diabetes, but they can also be used to treat other conditions such as high blood pressure or obesity.
Some of the key players operating in the hypoglycemic drugs market are Sanofi, Merck & Co., Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Novartis, Johnson & Johnson, AstraZeneca, Takeda, Bayer, Tonghua DongBao, Hua Dong.
The hypoglycemic drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hypoglycemic Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hypoglycemic Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hypoglycemic Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hypoglycemic Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hypoglycemic Drugs Market Size & Forecast, 2020-2028
4.5.1 Hypoglycemic Drugs Market Size and Y-o-Y Growth
4.5.2 Hypoglycemic Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Insulin
5.2.2 DPP-4
5.2.3 GLP-1
5.2.4 SGLT-2
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Type 1 Diabetes
6.2.2 Type 2 Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hypoglycemic Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hypoglycemic Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Insulin
9.6.2 DPP-4
9.6.3 GLP-1
9.6.4 SGLT-2
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Type 1 Diabetes
9.10.2 Type 2 Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Insulin
10.6.2 DPP-4
10.6.3 GLP-1
10.6.4 SGLT-2
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Type 1 Diabetes
10.10.2 Type 2 Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Insulin
11.6.2 DPP-4
11.6.3 GLP-1
11.6.4 SGLT-2
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Type 1 Diabetes
11.10.2 Type 2 Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Insulin
12.6.2 DPP-4
12.6.3 GLP-1
12.6.4 SGLT-2
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Type 1 Diabetes
12.10.2 Type 2 Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Insulin
13.6.2 DPP-4
13.6.3 GLP-1
13.6.4 SGLT-2
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Type 1 Diabetes
13.10.2 Type 2 Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hypoglycemic Drugs Market: Competitive Dashboard
14.2 Global Hypoglycemic Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Merck & Co.
14.3.3 Novo Nordisk
14.3.4 Eli Lilly
14.3.5 Boehringer Ingelheim
14.3.6 Novartis
14.3.7 Johnson & Johnson
14.3.8 AstraZeneca
14.3.9 Takeda
14.3.10 Bayer
14.3.11 Tonghua DongBao
14.3.12 Hua Dong
